Fujian Wanchen Biotechnology Co. Ltd (300972) Fair Value & Analysis
Consumer Defensive · CN · Market cap 37.8B CNY (≈ $5.6B) · ISIN CNE100004KH1
What is Fujian Wanchen Biotechnology Co. Ltd really worth?
A solid business, but trading 29% above our fair value of ¥143.09.
Strengths
Risks
For context
Fair value as of: Aug 22, 2026
From 24 valuation models · updated 14 days ago
Share price −10.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The model range is unusually wide (¥107.32 to ¥405.52). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range ¥10.23 – ¥232.89 · fair‑value band ¥107.32 – ¥405.52 · the ¥184.35 price screens above the ¥143.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Fujian Wanchen Biotechnology Co. Ltd (300972) currently trades at ¥184.35, while our model-based Fair Value estimate is ¥143.09, implying the stock looks roughly 28.8% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Consumer Defensive sector. Bull case: the Growth DCF group reads highest at a median of ¥416.62 per share, and 17 of the 24 models we run sit above the ¥184.35 price. Bear case: the Economic Profit group reads lowest at ¥83.21, and 7 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Fujian Wanchen Biotechnology Co. Ltd generated revenue of 57.3B CNY at a net margin of 3.1%. Revenue grew 53.7% year over year. It earns a return on equity of 114.0%. Net debt stands at 144M CNY. Fundamentals as of Aug 22, 2026
Our scenario range runs from ¥107.32 (bear case) to ¥405.52 (bull case); at ¥184.35, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 31% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 18% fair-value upside, at −22%, 300972 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥5.31 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth DCF (¥416.62) versus Asset-Based (¥5.04). Highest evidence: FCF DCF (73).
Notify me when 300972 reaches fair value
Put 300972 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Fujian Wanchen Food Group Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company provides white and golden enoki, crab, white jade, deer antler, seafood, oyster, and other mushrooms products.
Full company description
Fujian Wanchen Food Group Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company provides white and golden enoki, crab, white jade, deer antler, seafood, oyster, and other mushrooms products. It is also involved in breeding and fruit testing to produce new variants of edible fungi. The company sells its products through supermarket chains, restaurants, and online food platforms. It exports its products. The company was formerly known as Fujian Wanchen Biotechnology Group Co.,Ltd. and changed its name to Fujian Wanchen Food Group Co., Ltd. in January 2026. Fujian Wanchen Food Group Co., Ltd. was founded in 2011 and is headquartered in Zhangpu, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fujian Wanchen Biotechnology Co. Ltd reported revenue of 51.5B CNY in FY2025 versus 435M CNY in FY2021, a compound +229.9%/yr. Reported net income was 1.3B CNY in FY2025, compounding +175.2%/yr from FY2021.
300972 screens 29% overvalued. Compare with Archer-Daniels-Midland Company →
Peer Group
Farm Products · 293 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Farm Products median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Archer-Daniels-Midland Company ADM | $81.54 | $38.02 | −53% |
| Muyuan Foods Group 002714 | ¥40.15 | ¥47.42 | +18% |
| Bunge Global SA BG | $111.57 | $56.19 | −50% |
| Tyson Foods, Inc TSN | $55.40 | $28.60 | −48% |
| Wens Foodstuff Group 300498 | ¥13.80 | ¥11.18 | −19% |
| Mowi ASA MOWI | kr 201.80 | kr 256.14 | +27% |
| United Plantations Berhad 2089 | 32.60 MYR | 23.34 MYR | −28% |
| Charoen Pokphand Foods Public Company CPF | 23.40 THB | 43.24 THB | +85% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 2,960 IDR | 6,818 IDR | +130% |
| L.D.C. S.A LOUP | €112.20 | €184.99 | +65% |
Compare Fujian Wanchen Biotechnology Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Fujian Wanchen Biotechnology Co. Ltd (300972) overvalued or undervalued?
What is the fair value of 300972?
What is the quality score of 300972?
What is the revenue of Fujian Wanchen Biotechnology Co. Ltd (300972)?
What is the net profit margin of 300972?
Does Fujian Wanchen Biotechnology Co. Ltd pay a dividend?
Watch Fujian Wanchen Biotechnology Co. Ltd in the live analysis
One click puts Fujian Wanchen Biotechnology Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.